Oncodesign Precision Medicine Société anonyme Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Philippe Genne

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Recent updates

CEO

Philippe Genne

no data

Tenure

Dr. Philippe Genne, Ph D., Founded Oncodesign Société Anonyme, serves as its Chairman of the Board and has been its Chief Executive Officer since May 18, 2010 and Chief Corporate Business Development Offic...

Oncodesign Precision Medicine Société anonyme Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Oncodesign Precision Medicine Société anonyme, Annual General Meeting, Jun 26, 2024

Oncodesign Precision Medicine Société Anonyme Approves the Nomination of Florence Dupré to the Board of Directors

Recent updates

No longer forecast to breakeven

Oncodesign Precision Medicine Reports Final Results of Its Phase 1 Study with Ripk2 Inhibitor Opm-101, with Strong Safety Data and No Cardiac Toxicity, Paving the Way for the Launch of Phase 1B/2A

New minor risk - Profitability

Consensus revenue estimates decrease by 30%, EPS upgraded

New major risk - Revenue and earnings growth

Oncodesign Precision Medicine Société anonyme to Report First Half, 2024 Results on Sep 30, 2024

OPM Announces Positive Results of Its Phase 1 in Healthy Volunteers with OPM-101: Strong Target Engagement With Excellent Safety Profile

Forecast to breakeven in 2025

New major risk - Shareholder dilution

Price target decreased by 9.8% to €2.48

Oncodesign Precision Medicine Société anonyme, Annual General Meeting, Jun 26, 2024

New major risk - Shareholder dilution

Oncodesign Precision Medicine Receives ERDF Fund Totalling €2.1 Million for its Comete Program

Oncodesign Precision Medicine Société anonyme announced that it has received €22 million in funding from Eurazeo SE and other investors

New major risk - Shareholder dilution

Oncodesign Precision Medicine Announces Positive Interim Results of Its Phase 1 Study Evaluating OPM-101 in Healthy Volunteers

New major risk - Share price stability

Oncodesign Precision Medicine Société Anonyme Approves the Nomination of Florence Dupré to the Board of Directors

Oncodesign Precision Medicine Announces Initiation of Phase I of its RIPK2 Inhibitor ODS-101, aNew Therapeutic Agent for IBD

Oncodesign Precision Medicine Société anonyme to Report Fiscal Year 2022 Results on Apr 04, 2023

Edmond de Rothschild Equity Strategies Management III S.à.r.l acquired 61.58% stakes in Oncodesign Precision Medicine Société anonyme (ENXTPA:MLOPM) from Philippe Genne and other managers and minority shareholder.

CEO

Tenure